Intech Biopharm

Intech Biopharm Stock-Based Compensation

The Stock-Based Compensation (SBC) of Intech Biopharm (6461.TWO) as of Oct 29, 2026 is 15.76 M TWD. In the previous year, Stock-Based Compensation (SBC) was 14.64 M TWD — a change of 7.67% (higher).

Stock-Based Compensation

15.76 MTWD

YoY

7.67%

Last updated:

Stock-Based Compensation (SBC) of Intech Biopharm is 2025 15.76 M TWD. Stock-Based Compensation (SBC) of Intech Biopharm was 2024 14.64 M TWD. It decreases by 7.67% higher compared to the previous year.

The Intech Biopharm Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2019
9.37 M TWD
Jan 1, 2020
4.30 M TWD
Jan 1, 2021
10.64 M TWD
Jan 1, 2022
16.89 M TWD
Jan 1, 2023
14.13 M TWD
Jan 1, 2024
14.64 M TWD
Jan 1, 2025
15.76 M TWD
The Intech Biopharm Stock-Based Compensation history
YEARStock-Based CompensationYoY
15.76 MTWD+7.67%
14.64 MTWD+3.63%
14.13 MTWD-16.35%
16.89 MTWD+58.78%
10.64 MTWD+147.56%
4.30 MTWD-54.16%
9.37 MTWD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Intech Biopharm Stock analysis

What does Intech Biopharm do? Intech Biopharm Ltd is a pharmaceutical company based in Taipei City, Taiwan. The company went public on July 15, 2014, with the ticker symbol 6461.TWO and ISIN TW0006461007. It operates within the Health Care sector, specifically in the Pharmaceuticals industry. Intech Biopharm focuses on developing drugs for obstructive airway diseases, including bronchial asthma and chronic obstructive pulmonary disease. The company's primary products are respiratory drugs, notably the Duasma hexafluoroacetone (HFA) metered-dose inhalers (MDIs) and the Synvent HFA MDIs. These products are distributed both domestically within Taiwan and internationally. The company maintains a website at http://www.intechbiopharm.com/ for further information. Intech Biopharm Ltd is engaged in the research, development, and distribution of pharmaceutical products targeting respiratory conditions, with a focus on innovative inhaler technologies. The firm's operations are centered on addressing unmet medical needs in respiratory care through its specialized drug formulations. Intech Biopharm is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intech Biopharm stock

Stock-Based Compensation (SBC) of Intech Biopharm is 15.76 M TWD in 2025.

Stock-Based Compensation (SBC) of Intech Biopharm changed from 14.64 M TWD to 15.76 M TWD, representing a 7.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Intech Biopharm since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s TWD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Intech Biopharm historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Cash Flow — Intech Biopharm

Operating Cash FlowCapital ExpendituresFree Cash FlowFCF per ShareDividends PaidShare BuybacksInvesting Cash FlowFinancing Cash FlowCapEx / RevenueCash Flow per ShareStock-Based CompensationChange in Working CapitalAcquisitions (Net)Net Change in CashCapEx/OCFFCF/Net IncomeFCF ConversionCash ConversionTotal Shareholder PayoutCapEx/D&A

All Key Metrics — Intech Biopharm